• Sandrine Lecour, Hans E Bøtker, Gianluigi Condorelli, Sean M Davidson, David Garcia-Dorado, Felix B Engel, Peter Ferdinandy, Gerd Heusch, Rosalinda Madonna, Michel Ovize, Marisol Ruiz-Meana, Rainer Schulz, Joost P G Sluijter, Linda W Van Laake, Derek M Yellon, and Derek J Hausenloy.
• Hatter Institute for Cardiovascular Research in Africa and MRC Inter-University Cape Heart Group, University of Cape Town, Cape Town, South Africa.
• Cardiovasc. Res. 2014 Dec 1;104(3):399-411.

AbstractIschaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.© The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.

12 keywords...

hide…